Navigation Links
NeurogesX to Present at Upcoming Fall Conferences
Date:9/2/2009

aceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these for
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX Appoints New Board Director and Audit Committee Chairman
2. NeurogesX Reports Second Quarter 2009 Results
3. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
4. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
5. NeurogesX Added to Russell 3000 Index
6. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
7. NeurogesX to Present at Needham Life Sciences Conference
8. NeurogesX Receives European Commission Approval for Qutenza(TM)
9. NeurogesX Reports First Quarter 2009 Results
10. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
11. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... Altadena, CA (PRWEB) January 14, 2014 ... Angeles County), California, and Montreal, Canada, has big ideas ... and non-fiction. The press's goals are to produce high-quality, ... e-books to support local businesses. , The first ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... The review process being used by the Food and Drug ... fails to weigh the full effects of the fish,s widespread ... this week,s Science . The salmon, whose genome ... the first genetically modified animal approved for human consumption in ...
... FRAMINGHAM, Mass. and SYDNEY, Nov. 18, 2010 HeartWare ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that CEO Doug Godshall is scheduled ... Piper Jaffray Health Care Conference on Tuesday, November 30, ...
... Patients with Relapsed or Refractory Solid Tumors ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:FDA review on transgenic salmon too narrow 2FDA review on transgenic salmon too narrow 3HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 3Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 4Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 5Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 6Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 7Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 8Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 9Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 10
(Date:4/23/2014)... million Food Standards Agency (FSA) project to map the ... , Norovirus outbreaks can rapidly affect large numbers ... strawberries infected 11,000 people in Germany, but there are ... cause infection and which foods are the most likely ... produce data that will help the FSA to develop ...
(Date:4/22/2014)... Coral Gables, Fla. (April 21, 2014) -- There are ... out their feathers and spread their colorful tails; satin ... them with blue and shiny objects; and European bitterling ... Each species has evolved a unique method to communicate ... "Signaling can have profound fitness ...
(Date:4/22/2014)... FL, April 22, 2014 Scientists from the Florida ... a protein complex that plays a critical but previously ... The study, which showed a novel role for a ... in the journal eLife , a publisher supported ... Society and the Wellcome Trust. , "This is a ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3Scientists identify critical new protein complex involved in learning and memory 2
... that it will launch a major long-term project to ... The project is made possible by a $10 million ... of Los Angeles-based Tennenbaum Capital Partners and philanthropist. The ... the ocean,s coastal ecosystems over a long period of ...
... University of Illinois cell and developmental Biology professor Fei ... study how myeloids, a type of blood stem cell, ... defense against infections and tissue damage. This approach offers ... myeloid differentiation, and may improve our ability to treat ...
... DCOctober 25, 2012Biomedical and health research and development (R&D) ... billion or 3% between FY10 and FY11 according to ... represents the first drop in overall spending since Research!America ... follows an uptick in research funding attributed to the ...
Cached Biology News:Smithsonian launches global marine biodiversity project with $10 million donation 2Smithsonian launches global marine biodiversity project with $10 million donation 3A new technique to study how myeloids become white blood cells 2US investment in biomedical and health research on downward trend 2
Quartz-Halogen, 100 W, High Intensity...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
...
Biology Products: